A Case of Ovarian Mesothelioma with VHL Mutation Diagnosed by Immunohistochemistry and Literature Review

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Nov 28

PMID 39605894

Authors

Ye Yao

Hao Yan

Jing Xiong

Yaqi Duan

Affiliations

Soon will be listed here.

Abstract

The malignant mesothelioma mainly develops in the pleura and peritoneum, while primary ovarian mesothelioma is very rare. Here, we report the first case of primary ovarian mesothelioma (clear cell variant) with VHL mutations in the world based on the results of histomorphology, immunohistochemistry, and genetic testing. This is an extremely rare type of tumor that has not been reported so far. Through the literature search, we reviewed primary ovarian mesothelioma, focusing on its differential diagnosis and molecular genetics. The purpose of this paper is to deepen the flexible selection and application of immunohistochemical markers in mesothelioma, so as to reduce missed diagnosis and misdiagnosis.

References

Fujiwara K, Shintani D, Nishikawa T . Clear-cell carcinoma of the ovary. Ann Oncol. 2016; 27 Suppl 1:i50-i52. DOI: 10.1093/annonc/mdw086. View

Kapoor R, Kuttikat P, Vaiphei K, Rai B, Patel F . A case report of peritoneal malignant mesothelioma presenting as primary ovarian mass. J Cancer Res Ther. 2015; 11(3):654. DOI: 10.4103/0973-1482.139382. View

Addis B, Fox H . Papillary mesothelioma of ovary. Histopathology. 1983; 7(2):287-98. DOI: 10.1111/j.1365-2559.1983.tb02242.x. View

Clement P, Young R, Scully R . Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol. 1996; 20(9):1067-80. DOI: 10.1097/00000478-199609000-00004. View

Tarade D, Ohh M . The HIF and other quandaries in VHL disease. Oncogene. 2017; 37(2):139-147. DOI: 10.1038/onc.2017.338. View

Ordonez N . Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases. Hum Pathol. 2005; 36(5):465-73. DOI: 10.1016/j.humpath.2005.02.014. View

Dagogo-Jack I, Madison R, Lennerz J, Chen K, Hopkins J, Schrock A . Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. JCO Precis Oncol. 2022; 6:e2100422. DOI: 10.1200/PO.21.00422. View

Butler H, Saulat O, Guinn B . Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review. Carcinogenesis. 2022; 43(3):183-189. PMC: 9036986. DOI: 10.1093/carcin/bgac012. View

Hayashi H, Kawata T, Shimokawa I . Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. Pathol Res Pract. 2017; 213(5):580-584. DOI: 10.1016/j.prp.2016.12.025. View

10.

Goldblum J, HART W . Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol. 1995; 19(10):1124-37. DOI: 10.1097/00000478-199510000-00003. View

11.

Ordonez N . Clear cell mesothelioma presenting as an incarcerated abdominal hernia. Virchows Arch. 2005; 447(5):823-7. DOI: 10.1007/s00428-005-0023-2. View

12.

Ordonez N, Myhre M, Mackay B . Clear cell mesothelioma. Ultrastruct Pathol. 1996; 20(4):331-6. DOI: 10.3109/01913129609016333. View

13.

Chapel D, Husain A, Krausz T, McGregor S . PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. Am J Surg Pathol. 2017; 41(12):1675-1682. DOI: 10.1097/PAS.0000000000000935. View

14.

Goldberg M, Imbernon E, Rolland P, Gilg Soit Ilg A, Saves M, de Quillacq A . The French National Mesothelioma Surveillance Program. Occup Environ Med. 2006; 63(6):390-5. PMC: 2078115. DOI: 10.1136/oem.2005.023200. View

15.

Iwamoto M, Nakatani Y, Fugo K, Kishimoto T, Kiyokawa T . Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum Pathol. 2015; 46(7):957-62. DOI: 10.1016/j.humpath.2015.03.008. View

16.

Husain A, Colby T, Ordonez N, Allen T, Attanoos R, Beasley M . Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2017; 142(1):89-108. DOI: 10.5858/arpa.2017-0124-RA. View

17.

Mishra A, Shet T . Clear cell mesothelioma of the testis with deciduoid areas--a case report. Indian J Pathol Microbiol. 2005; 47(4):544-6. View

18.

Ettinger D, Wood D, Stevenson J, Aisner D, Akerley W, Bauman J . Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023; 21(9):961-979. DOI: 10.6004/jnccn.2023.0045. View

19.

Hsieh J, Le V, Oyama T, Ricketts C, Ho T, Cheng E . Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2018; :JCO2018792549. PMC: 6299341. DOI: 10.1200/JCO.2018.79.2549. View

20.

Smith-Hannah A, Naous R . Primary peritoneal epithelioid mesothelioma of clear cell type with a novel VHL gene mutation: a case report. Hum Pathol. 2018; 83:199-203. DOI: 10.1016/j.humpath.2018.07.033. View